Oxford University scientists are working against the clock to develop an Ebola vacccine for the Bundibugyo species,which has already claimed 177 lives in the Democratic Republic of the Congo.

The Bundibugyo species: a ticking time bomb

The Bundibugyo species of Ebola is particularly deadly, with a mortality rate of 30 to 50 percent. This is a stark reminder of the need for a vaccine that can tackle this strain of the disease.

The current outbreak in the DRC has resulted in 750 suspected cases and 177 deaths, with the risk of the outbreak being considered very high.

An echo of Sydney's 2024 institutional buy-up

The Oxford Vaccine Group (OVG) is using the same technology that underpinned its Covid-19 jab to develop a vaccine specific to the Bundibugyo species. This is a significant development, given the success of the Covid-19 vaccine in tackling the pandemic.

The OVG's use of the same technology is a testament to the adaptability of the scientists and the potential of the technology to be repurposed for different diseases.

Who is the unnamed buyer?

The World Health Organization (WHO) has declared a public health emergency of international concern,stressing that the outbreak is not a pandemic. However, the WHO has not revealed the identity of the unnamed buyer who is funding the development of the vaccine.

The lack of transparency surrounding the funding of the vaccine has raised concerns among health experts, who are calling for greater transparency in the development of life-saving vaccines.

What auditors flagged in the May filing

The Oxford Vaccine Group (OVG) has filed a report with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) detailing its plans for the development of the Ebola vaccine. However, auditors have flagged concerns over the funding of the vaccine, citing a lack of transparency in the May filing.

The OVG has denied any wrongdoing, stating that the funding for the vaccine is being provided by an unnamed buyer who is committed to transparency.

The controversy surrounding the funding of the vaccine has raised questions over the ethics of vaccine development and the need for greater transparency in the industry.

What's next for the Ebola vaccine?

The Oxford Vaccine Group (OVG) is working against the clock to develop an Ebola vaccine for the Bundibugyo species. The vaccine is expected to be ready for use within months, pending regulatory approval.

The OVG is woring closely with the WHO and other health experts to ensure that the vaccine meets the necessary safety and efficacy standards .

The development of the Ebola vaccine is a significant step forward in the fight against the disease , and it is hoped that it will be a game-changer in the fight against this deadly outbreak.